Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.